Filed Pursuant to Rule
424(b)(3)
Registration No. 333-266162
PROSPECTUS
Staffing
360 Solutions, Inc.
2,022,913
Shares of Common Stock
This
prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 2,022,913 shares of
our common stock, par value $0.00001 per share. These 2,022,913 shares of common stock consist of:
● |
409,531
shares of common stock, or the Common Shares, that were issued in the July 2022 Private Placement (as defined herein), pursuant to
the securities purchase agreement, dated as of July 1, 2022, by and among us and the several purchasers named therein, or the July
2022 Purchase Agreement; |
|
|
● |
248,327
shares of common stock, or the Pre-Funded Warrant Shares, issuable upon the exercise of certain pre-funded warrants, or the Pre-Funded
Warrants, that were issued pursuant to the July 2022 Purchase Agreement in the July 2022 Private Placement; |
|
|
● |
657,858
shares of common stock, or the Amended Warrant Shares, issuable upon the exercise of certain existing warrants, or the Amended Warrants,
that were amended pursuant to the warrant amendment agreements, or the Warrant Amendment Agreements, entered into by the selling
shareholders in the July 2022 Private Placement; |
|
|
● |
657,858
shares of common stock, or the Warrant Shares, issuable upon the exercise of warrants, or the Warrants, that were issued pursuant
to the July 2022 Purchase Agreement in the July 2022 Private Placement; and |
|
|
● |
49,339
shares of common stock, or the Wainwright Warrant Shares, issuable upon the exercise of warrants, or the Wainwright Warrants, that
were issued to H.C. Wainwright & Co., LLC, or Wainwright, as part of Wainwright’s compensation for serving as exclusive
placement agent in connection with the July 2022 Private Placement; |
The
Common Shares, the Pre-Funded Warrants, the Amended Warrants, the Warrants and the Wainwright Warrants were issued in reliance upon the
exemption from the registration requirements in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. Each purchaser
represented that it was an “accredited investor” (as defined by Rule 501 under the Securities Act). We are registering the
offer and resale of the Common Shares and the Pre-Funded Warrant Shares, Warrant Shares issuable upon the exercise of the Pre-Funded
Warrants and the Warrants to satisfy a provision in that certain registration rights agreement, dated July 1, 2022, or the Registration
Rights Agreement, pursuant to which we agreed to register the resale of the Common Shares and the shares of common stock issuable upon
the exercise of the Pre-Funded Warrants, and the Warrants. We are also registering the shares of common stock issuable upon the exercise
of the Amended Warrants and the Wainwright Warrants in order to permit the selling stockholders to offer the Amended Warrant Shares and
the Wainwright Warrant Shares for resale from time to time pursuant to this prospectus
Our
registration of the shares of common stock covered by this prospectus does not mean that the selling stockholders will offer or sell
any of such shares of common stock. The selling stockholders named in this prospectus, or their donees, pledgees, transferees or other
successors-in-interest, may resell the shares of common stock covered by this prospectus through public or private transactions at prevailing
market prices, at prices related to prevailing market prices or at privately negotiated prices. For additional information on the possible
methods of sale that may be used by the selling stockholders, you should refer to the section of this prospectus entitled “Plan
of Distribution.”
We
will not receive any of the proceeds from the sale of common stock by the selling stockholders. However, we will receive proceeds from
the exercise of the Pre-Funded Warrants, the Amended Warrants, the Warrants and the Wainwright Warrants if the Pre-Funded Warrants, the
Amended Warrants, the Warrants and the Wainwright Warrants are exercised for cash. We intend to use those proceeds, if any, for working
capital purposes.
Any
shares of common stock subject to resale hereunder will have been issued by us and acquired by the selling stockholders prior to any
resale of such shares pursuant to this prospectus.
No
underwriter or other person has been engaged to facilitate the sale of the common stock in this offering. We will bear all costs, expenses
and fees in connection with the registration of the common stock. The selling stockholders will bear all commissions and discounts, if
any, attributable to their respective sales of our common stock.
Effective
as of 4:05 pm Eastern Time on June 23, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation,
or the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of our common stock, at a ratio
of 1-for-10. All share and per share prices in this prospectus have been adjusted to reflect the 1-for-10 Reverse Stock Split (as defined
herein); however, common stock share and per share amounts in certain of the documents incorporated by reference herein have not been
adjusted to give effect to the 1-for-10 Reverse Stock Split.
Our
common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “STAF.” On July 14, 2022, the last reported
sales price for our common stock was $3.73 per share.
Investment
in our common stock involves risk. See “Risk Factors” contained in this prospectus, in our periodic reports filed from time
to time with the Securities and Exchange Commission, which are incorporated by reference in this prospectus and in any applicable prospectus
supplement. You should carefully read this prospectus and the documents we incorporate by reference, before you invest in our common
stock.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or the accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is July 20, 2022.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of the registration statement that we filed with the Securities and Exchange Commission pursuant to which the selling
stockholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this
prospectus. As permitted by the rules and regulations of the Securities and Exchange Commission, the registration statement filed by
us includes additional information not contained in this prospectus.
This
prospectus and the documents incorporated by reference into this prospectus include important information about us, the securities being
offered and other information you should know before investing in our securities. You should not assume that the information contained
in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information
we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though
this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to
read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making
your investment decision. You should also read and consider the information in the documents to which we have referred you under “Where
You Can Find More Information” and “Incorporation of Certain Information by Reference” in this prospectus.
You
should rely only on this prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus. We
have not, and the selling stockholders have not, authorized anyone to give any information or to make any representation to you other
than those contained or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information,
you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy securities in
any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in
some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.
Unless
otherwise indicated, information contained or incorporated by reference in this prospectus concerning our industry, including our general
expectations and market opportunity, is based on information from our own management estimates and research, as well as from industry
and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly
available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be
reasonable. In addition, assumptions and estimates of our and our industry’s future performance are necessarily uncertain due to
a variety of factors, including those described in “Risk Factors” beginning on page 5 of this prospectus. These and other
factors could cause our future performance to differ materially from our assumptions and estimates.
PROSPECTUS
SUMMARY
This
summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does not
contain all of the information you should consider before investing in our securities. You should carefully read the prospectus, the
information incorporated by reference and the registration statement of which this prospectus is a part in their entirety before investing
in our securities, including the information discussed under “Risk Factors” in this prospectus and the documents incorporated
by reference and our financial statements and related notes that are incorporated by reference in this prospectus. In this prospectus,
unless the context indicates otherwise, “Staffing 360,” the “Company,” the “registrant,” “we,”
“us,” “our,” or “ours” refer to Staffing 360 Solutions, Inc. and its consolidated subsidiaries.
Overview
We
are a high-growth international staffing company engaged in the acquisition of United States and United Kingdom based staffing companies.
Our services principally consist of providing temporary contractors, and, to a much lesser extent, the recruitment of candidates for
permanent placement. As part of our consolidation model, we pursue a broad spectrum of staffing companies supporting primarily accounting
and finance, IT, engineering, administration and commercial disciplines. Our typical acquisition model is based on paying consideration
in the form of cash, stock, earn-outs and/or promissory notes. In furthering our business model, we are regularly in discussions and
negotiations with various suitable, mature acquisition targets. To date, we have completed eleven acquisitions since November 2013.
Recent
Developments
Amendment
to Articles of Incorporation
On
June 23, 2022, we filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”)
with the Secretary of State of Delaware to effect a 1-for-10 reverse stock split of the shares of our common stock, either issued and
outstanding or held us as treasury stock, effective as of 4:05 p.m. (Delaware time) on June 23, 2022 (the “1-for-10 Reverse Stock
Split”). As previously reported on our Current Report on Form 8-K, filed on June 23, 2022, we held a special meeting of stockholders
on June 23, 2022 (the “Special Meeting”), at which meeting our stockholders, by an affirmative vote of the majority of our
outstanding shares of capital stock (including holders of our Series H Convertible Preferred Stock, voting on an as-converted basis and
Series J Preferred Stock), approved the amendment to our Certificate of Incorporation to effect, at the discretion of our Board of Directors
(the “Board”), a reverse stock split (the “Approved Reverse Stock Split”) of the common stock at a ratio determined
by the Board in the range of 1-for-2 to 1-for-20, such ratio to be determined by the Board, without reducing the authorized number of
shares of common stock. Following the Special Meeting, the Board determined to effect the Approved Reverse Stock Split at a ratio of
1-for-10 and approved the corresponding final form of the Certificate of Amendment.
As
a result of the 1-for-10 Reverse Stock Split, every ten shares of issued and outstanding common stock were automatically combined on
June 23, 2022 into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares
were issued as a result of the 1-for-10 Reverse Stock Split. Any fractional shares that would otherwise have resulted from the 1-for-10
Reverse Stock Split were rounded up to the next whole number. The 1-for-10 Reverse Stock Split reduced the number of shares of common
stock outstanding from 17,618,300 shares to approximately 1,761,830 shares, subject to adjustment for the rounding up of fractional shares.
The number of authorized shares of common stock under the Certificate of Incorporation remained unchanged at 200,000,000 shares.
Proportionate
adjustments will be made to the number of shares of common stock that may be received upon conversion of the issued and outstanding shares
of our Series H Convertible Preferred Stock. In addition, proportionate adjustments will be made to the per share exercise price and
the number of shares of common stock that may be purchased upon exercise of outstanding stock options granted by us, and the number of
shares of common stock reserved for future issuance under our 2014 Equity Incentive Plan, 2015 Omnibus Plan, 2016 Omnibus Plan and 2020
Omnibus Plan.
The
common stock began trading on a reverse stock split-adjusted basis on Nasdaq on June 24, 2022. The trading symbol for the common stock
remains “STAF.” The new CUSIP number for the common stock following the 1-for-10 Reverse Stock Split is 852387505.
July
2022 Private Placement
On
July 1, 2022, we entered into the July 2022 Purchase Agreement with certain institutional and accredited investors. Pursuant to the July
2022 Purchase Agreement, we sold, in a private placement (the “July 2022 Private Placement”), 657,858 shares of our common
stock (or pre-funded warrants) and warrants to purchase up to an aggregate of 657,858 shares of our common stock to the investors at
a combined purchase price of $6.10 per share (or pre-funded warrant) and associated warrant. The Pre-Funded Warrants are exercisable
at a price of $0.00001 per share, are exercisable immediately upon issuance and are exercisable until the Pre-Funded Warrants are exercised
in full. The Warrants are exercisable at an exercise price of $5.85 per share, were exercisable immediately upon issuance and have a
term of exercise equal to five and one-half years from the date of issuance.
The
net proceeds to us from the July 2022 Private Placement were approximately $3.08 million, after deducting placement agent fees and other
estimated offering expenses payable by us.
On
June 28, 2022, we entered into an engagement letter (the “Engagement Letter”) with Wainwright, pursuant to which Wainwright
agreed to serve as our exclusive placement agent, on a reasonable best-efforts basis, in connection with the July 2022 Private Placement.
We paid Wainwright an aggregate cash fee equal to 7.5% of the gross proceeds of the July 2022 Private Placement and a management fee
equal to 1.0% of the gross proceeds of the July 2022 Private Placement, and additionally reimbursed Wainwright for a non-accountable
expense allowance of $85,000. Additionally, we issued to Wainwright or its designees as compensation, the Wainwright Warrants to purchase
up to 49,339 shares of common stock, equal to 7.5% of the aggregate number of shares of common stock placed in the July 2022 Private
Placement. The Wainwright Warrants have a term of five and one-half years from the date of issuance and an exercise price of $7.625 per
share of common stock (equal to 125% of the combined purchase price per share of common stock (or pre-funded warrant) and associated
warrant issued and sold in the July 2022 Private Placement). The July 2022 Private Placement closed on July 7, 2022.
Corporate
Information
Staffing
360 Solutions, Inc., was incorporated in the State of Nevada on December 22, 2009, as Golden Fork Corporation, which changed its name
to Staffing 360 Solutions, Inc., and its trading symbol to “STAF”, on March 16, 2012. On June 15, 2017, we changed our state
of domicile to the State of Delaware. Our principal executive office is located at 757 Third Avenue, 27th Floor, New York, New York 10017,
and our telephone number is (646) 507-5710. Our website is www.staffing360solutions.com, and the information included in, or linked to
our website is not part of this prospectus. We have included our website address in this prospectus solely as a textual reference.
THE
OFFERING
Common
Stock to be Offered by the selling stockholders |
|
Up
to 2,022,913 shares of our common stock, which are comprised of (i) 409,531 Common Shares, (ii) 248,327 shares of common stock issuable
upon the exercise of the Pre-Funded Warrants, (iii) 657,858 shares of common stock issuable upon the exercise of the Amended Warrants,
(iv) 657,858 shares of common stock issuable upon the exercise of the Warrants, and (v) 49,339 shares of common stock issuable upon
the exercise of the Wainwright Warrants. |
|
|
|
Use
of Proceeds |
|
All
shares of our common stock offered by this prospectus are being registered for the accounts of the selling stockholders and we will
not receive any proceeds from the sale of these shares. However, we will receive proceeds from the exercise of the Pre-Funded Warrants,
the Amended Warrants, the Warrants and the Wainwright Warrants if the Pre-Funded Warrants, the Amended Warrants, the Warrants and
the Wainwright Warrants are exercised for cash. We intend to use those proceeds, if any, for working capital purposes. See “Use
of Proceeds” beginning on page 8 of this prospectus for additional information. |
|
|
|
Registration
Rights |
|
Under
the terms of the Registration Rights Agreement, we agreed to file this registration statement with respect to the registration of
the resale by the selling stockholders of shares of common stock issuable pursuant to the July 2022 Purchase Agreement and the exercise
of the Pre-Funded Warrants and the Warrants, as applicable, by the 15th calendar day following the date of the Registration Rights
Agreement, and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and
in any event, no later than the 45th calendar day following the date of the Registration Rights Agreement. In addition, we agreed
that, upon the registration statement being declared effective under the Securities Act of 1933, as amended (the “Securities
Act”), we will use our best efforts to maintain the effectiveness of the registration statement until the date that (i) the
selling stockholders have sold all of the shares of common stock issuable under the Registration Rights Agreement or (ii) such shares
may be resold by the selling stockholders pursuant to Rule 144 of the Securities Act, without the requirement for us to be in compliance
with the current public information required under such rule and without volume or manner-of-sale restriction. |
|
|
|
Plan
of Distribution |
|
The
selling stockholders named in this prospectus, or their pledgees, donees, transferees, distributees,
beneficiaries or other successors-in-interest, may offer or sell the shares of common stock
from time to time through public or private transactions at prevailing market prices, at
prices related to prevailing market prices or at privately negotiated prices. The selling
stockholders may also resell the shares of common stock to or through underwriters, broker-dealers
or agents, who may receive compensation in the form of discounts, concessions or commissions.
See
“Plan of Distribution” beginning on page 16 of this prospectus for additional information on the methods of sale that
may be used by the selling stockholders. |
|
|
|
Nasdaq
Capital Market Symbol |
|
Our
common stock is listed on Nasdaq under the symbol “STAF.” |
|
|
|
Risk
Factors |
|
Investing
in our common stock involves significant risks. See “Risk Factors” beginning on page 5 of this prospectus and the documents
incorporated by reference in this prospectus. |
RISK
FACTORS
An
investment in our securities involves certain risks. Before deciding to invest in our common stock, you should consider carefully the
following discussion of risks and uncertainties affecting us and our securities, together with other information in this prospectus and
the other information and documents incorporated by reference in this prospectus, including the risks, uncertainties and assumptions
discussed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K for the fiscal year ended January
1, 2022, or any updates in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Our business, business prospects, financial
condition or results of operations could be seriously harmed as a result of these risks. This could cause the trading price of our common
stock to decline, resulting in a loss of all or part of your investment. Additional risks and uncertainties not presently known to us
or that we currently deem immaterial also may materially and adversely affect our business, financial condition and results of operations.
Please also read carefully the section below entitled “Special Note Regarding Forward-Looking Statements.”
Risks
Related to Our Business
The
COVID-19 pandemic has adversely affected our business and may continue to adversely affect our business.
In
December 2019, a strain of coronavirus was reported to have surfaced in Wuhan, China, and spread globally. The COVID-19 pandemic has,
from time to time, led to government-imposed quarantines, limitations on business activity and shelter-in-place mandates to mitigate
or contain the virus, and has contributed to financial market volatility and uncertainty, significant disruptions in general commercial
activity and the global economy, including in the United States and the United Kingdom where our operations are based. Much of the independent
contractor work we provide to our clients is performed at the site of our clients. As a result, we are subject to the plans and approaches
of our clients have made to address the COVID-19 pandemic, such as whether they support remote working or if they have simply closed
their facilities and furloughed employees. To the extent that our clients were to decide or are required to close their facilities, or
not permit remote work when they close facilities, we would no longer generate revenue and profit from that client. In addition, in the
event that our clients’ businesses suffer or close as a result of the COVID-19 pandemic, we may experience decline in our revenue
or write-off of receivables from such clients. Developments such as social distancing and shelter-in-place directives have impacted our
ability to deploy our staffing workforce effectively during the COVID-19 pandemic, thereby impacting contracts with customers in our
commercial staffing and professional staffing business streams, and may continue to impact our business and results of operations should
such measures be implemented again. While some government-imposed precautionary measures have been relaxed in certain countries or states,
more strict measures may be put in place again due to a resurgence in COVID-19 cases or emergence of new variants of the virus.
Our
business was impacted in the fiscal year ended January 1, 2022, by numerous government-mandated lockdown periods in the United States
and United Kingdom. This had a large impact on the financial results of our numerous business streams, which differed in their financial
recoveries primarily due to the geographies and industries in which they operate.
The
ultimate impact of the COVID-19 pandemic continues to be highly uncertain and subject to future developments. A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital
and on the market price of our common stock, and affect our ability to successfully raise needed capital. If we are unsuccessful in raising
capital in the future, we may need to reduce activities, curtail or cease operations. The ongoing COVID-19 pandemic may continue to disrupt
the marketplaces in which we operate, which may negatively affect our business, results of operations and overall liquidity, as it has
previously.
Risks
Related to Our Common Stock and this Offering
We
may not meet the continued listing requirements of The Nasdaq Capital Market, which could result in a delisting of our common stock.
Our
common stock is listed on Nasdaq. We have in the past, and may in the future, be unable to comply with certain of the listing standards
that we are required to meet to maintain the listing of our common shares on Nasdaq.
On
April 27, 2021, we received a letter from the Listing Qualifications Department of Nasdaq (the “Staff”) indicating that,
based upon the closing bid price of our common stock for the 30 consecutive business day period between March 12, 2021 through April
27, 2021, we did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing
Rule 5550(a)(2) (the “Bid Price Requirement”). On July 27, 2021, we received notice from Nasdaq indicating that we had regained
compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
On
February 23, 2022, we received a letter from the Listing Qualifications of Nasdaq notifying us that we were no longer in compliance with
the Bid Price Requirement, for continued listing on Nasdaq. Pursuant to the Panel Decision (as defined below) dated June 28, 2021, we
were not eligible for the 180-day bid price compliance period set forth in the Listing Rules. As a result, we were subject to delisting
from Nasdaq unless we timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”). We had a hearing before the
Panel on March 30, 2022, which automatically stayed any suspension or delisting action pending the issuance of a decision by the Panel
following the hearing and the expiration of any additional extension period granted by the Panel following the hearing. On April 12,
2022, we received a letter from Nasdaq notifying us that the Panel determined to grant our request for continued listing on Nasdaq, subject
to the following: (i) on or about May 2, 2022, we advised the Panel of the status of the proxy statement it plans to file to obtain shareholder
approval for a reverse stock split, (ii) on or about May 23, 2022, we advised the Panel on the status of the shareholder meeting we plan
to hold to obtain approval of the reverse stock split, (iii) on or about May 26, 2022, we will affect a reverse stock split and (iv)
on or before about June 22, 2022, we shall demonstrate compliance with the Bid Price Requirement by evidencing a closing bid price above
$1.00 per share for the previous ten consecutive trading sessions. On April 19, 2022, we received a letter from the Staff notifying us
that as we had not yet filed our Form 10-K for the period ended January 1, 2022, such matter serves as an additional basis for delisting
our securities from Nasdaq under Nasdaq Listing Rule 5810(c)(2)(A). On May 4, 2022 the Panel granted us an extension request until July
11, 2022 to demonstrate compliance with the bid price requirement. On May 20, 2022, we received a notice from the Staff notifying us
that as we had not yet filed our Form 10-Q for the period ended April 2, 2022, such matter serves as a basis for delisting our securities
from Nasdaq in addition to the aforementioned matters. On June 23, 2022, we effected the 1-for-10 Reverse Stock Split, on June 24, 2022,
we filed our Annual Report on Form 10-K for the year ended January 1, 2022, and on July 14, 2022, we filed our Quarterly
Report on Form 10-Q for the period ended April 2, 2022.
On
June 3, 2020, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that we were no longer in compliance
with the minimum stockholders’ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1) to maintain
stockholders’ equity of at least $2,500,000. A hearing before the Panel was held on January 21, 2021, and we were granted an extension
to regain compliance until February 28, 2021, which was subsequently further extended to May 31, 2021 (the “Panel Decision”).
On June 11, 2021, we received a letter from the Staff notifying us that the Panel had determined to delist our shares from Nasdaq and
that trading in our shares would be suspended effective at the open of business on June 15, 2021 but that due to a procedural issue,
the Panel determined not to implement the decision and afforded us an opportunity to make an additional submission for the Panel’s
consideration. On June 28, 2021, we received a letter from the Staff informing us that we had regained compliance with the Rule. As a
result, the Panel determined to continue the listing of our securities on Nasdaq. The Panel also determined to impose a Panel Monitor
under Listing Rule 5815(d)(4)(A) for a period of one year from the date of the June 28, 2021 letter (the “Monitoring Period”).
We were expected to remain in compliance with all of Nasdaq’s continued listing requirements during the Monitoring Period.
If
Nasdaq delists our common stock from trading on its exchange for failure to meet the listing standards, an investor would likely find
it significantly more difficult to dispose of or obtain our shares, and our ability to raise future capital through the sale of our shares
could be severely limited. We additionally may not be able to list our common stock on another national securities exchange, which could
result in our securities being quoted on an over-the-counter market. If this were to occur, our shareholders could face significant material
adverse consequences, including limited availability of market quotations for our common stock and reduced liquidity for the trading
of our securities. In addition, we could experience a decreased ability to issue additional securities and obtain additional financing
in the future. There can be no assurance that an active trading market for our common stock will develop or be sustained. Delisting could
also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest
and fewer business development opportunities.
There
may be future sales of our securities or other dilution of our equity, which may adversely affect the market price of our common stock.
We
are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable
for, or that represent the right to receive, common stock. The market price of our common stock could decline as a result of sales of
common stock or securities that are convertible into or exchangeable for, or that represent the right to receive, common stock after
this offering or the perception that such sales could occur.
A
more active, liquid trading market for our common stock may not develop, and the price of our common stock may fluctuate significantly.
Historically,
the market price of our common stock has fluctuated over a wide range. During the 12-month period prior to the date of this
prospectus, after giving effect to the 1-for 10 Reverse Stock Split, our common stock traded as high as $47.40 per share and as low
as $3.60 per share. There has been relatively limited trading volume in the market for our common stock, and a more active, liquid
public trading market may not develop or may not be sustained. Limited liquidity in the trading market for our common stock may
adversely affect a stockholder’s ability to sell its shares of common stock at the time it wishes to sell them or at a price
that it considers acceptable. If a more active, liquid public trading market does not develop we may be limited in our ability to
raise capital by selling shares of common stock and our ability to acquire other companies or assets by using shares of our common
stock as consideration. In addition, if there is a thin trading market or “float” for our stock, the market price for
our common stock may fluctuate significantly more than the stock market as a whole. Without a large float, our common stock would be
less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may
be more volatile and it would be harder for a stockholder to liquidate any investment in our common stock. Furthermore, the stock
market is subject to significant price and volume fluctuations, and the price of our common stock could fluctuate widely in response
to several factors, including:
|
● |
our
quarterly or annual operating results; |
|
● |
changes
in our earnings estimates; |
|
● |
investment
recommendations by securities analysts following our business or our industry; |
|
● |
additions
or departures of key personnel; |
|
● |
changes
in the business, earnings estimates or market perceptions of our competitors; |
|
● |
our
failure to achieve operating results consistent with securities analysts’ projections; |
|
● |
changes
in industry, general market or economic conditions; and |
|
● |
announcements
of legislative or regulatory changes. |
The
stock market has experienced extreme price and volume fluctuations in recent years that have significantly affected the quoted prices
of the securities of many companies, including companies in the staffing industry. The changes often appear to occur without regard to
specific operating performance. The price of our common stock could fluctuate based upon factors that have little or nothing to do with
us and these fluctuations could materially reduce our stock price.
We
do not anticipate paying dividends on our common stock and, accordingly, stockholders must rely on stock appreciation for any return
on their investment.
We
initiated a dividend program in early 2019 under which we intended to pay a regular quarterly cash dividend of $0.10 per share to holders
of our common stock. The first such dividend was paid on February 28, 2019 to shareholders of record as of February 15, 2019, but subsequent
dividends were suspended by our Board. In the future, our Board may, without advance notice, determine to initiate, reduce or suspend
our dividends in order to maintain our financial flexibility and best position us for long-term success. The declaration and amount of
future dividends is at the discretion of our Board and will depend on our financial condition, results of operations, cash flows, prospects,
industry conditions, capital requirements and other factors and restrictions our Board deems relevant. In addition, we are limited in
our ability to pay dividends by certain of our existing agreements. In particular, our debt agreements only permit us to pay a quarterly
cash dividend of one cent per share of common stock issued and outstanding, provided, that such cash dividend does not exceed $100 in
the aggregate per fiscal quarter. We may not pay such dividends if any events of default exist under our debt agreements.
Accordingly,
we cannot be certain if we will be able to pay quarterly cash dividends to holders of our common stock in the foreseeable future. Consequently,
investors must mainly rely on sales of their common stock after price appreciation, which may never occur, as the primary way to realize
any future gains on their investment. There is no guarantee that shares of our common stock will appreciate in value or even maintain
the price at which our stockholders have purchased their shares.
The
1-for-10 Reverse Stock Split may decrease the liquidity of the shares of our common stock.
The
liquidity of the shares of our common stock may be affected adversely by the 1-for-10 Reverse Stock Split given the reduced number of
shares that are outstanding following the 1-for-10 Reverse Stock Split. In addition, the 1-for-10 Reverse Stock Split would have increased
the number of stockholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders
to experience an increase in the cost of selling their shares and greater difficulty effecting such sales.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the information incorporated by reference in this prospectus contain “forward-looking statements,” which include
information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation.
Our use of the words “may,” “will,” “would,” “could,” “should,” “believes,”
“estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,”
“intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,”
“impacts,” “forecasts,” “target,” “outlook,” “initiative,” “objective,”
“designed,” “priorities,” “goal” or the negative of those words or other similar expressions is intended
to identify forward-looking statements that represent our current judgment about possible future events. Forward-looking statements should
not be read as a guarantee of future performance or results and will probably not be accurate indications of when such performance or
results will be achieved. All statements included or incorporated by reference in this prospectus, and in related comments by our management,
other than statements of historical facts, including without limitation, statements about future events or financial performance, are
forward-looking statements that involve certain risks and uncertainties.
These
statements are based on certain assumptions and analyses made in light of our experience and perception of historical trends, current
conditions and expected future developments as well as other factors that we believe are appropriate in the circumstances. While these
statements represent our judgment on what the future may hold, and we believe these judgments are reasonable, these statements are not
guarantees of any events or financial results. Whether actual future results and developments will conform with our expectations and
predictions is subject to a number of risks and uncertainties, including the risks and uncertainties discussed in this prospectus, any
prospectus supplement and the documents incorporated by reference under the captions “Risk Factors” and “Special Note
Regarding Forward-Looking Statements” and elsewhere in those documents.
Consequently,
all of the forward-looking statements made in this prospectus as well as all of the forward-looking statements incorporated by reference
to our filings under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are qualified by these cautionary
statements and there can be no assurance that the actual results or developments that we anticipate will be realized or, even if realized,
that they will have the expected consequences to or effects on us and our subsidiaries or our businesses or operations. We caution investors
not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly or otherwise revise any forward-looking
statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements,
except where we are expressly required to do so by law.
USE
OF PROCEEDS
All
shares of our common stock offered by this prospectus are being registered for the accounts of the selling stockholders and we will not
receive any proceeds from the sale of these shares. However, we will receive proceeds from the exercise of the Pre-Funded Warrants, the
Amended Warrants, the Warrants and the Wainwright Warrants if the Pre-Funded Warrants, the Amended Warrants, the Warrants and the Wainwright
Warrants are exercised for cash. We intend to use those proceeds, if any, for working capital purposes.
SELLING
STOCKHOLDERS
Unless
the context otherwise requires, as used in this prospectus, “selling stockholders” includes the selling stockholders listed
below and donees, pledgees, transferees or other successors-in-interest selling shares received after the date of this prospectus from
the selling stockholders as a gift, pledge or other non-sale related transfer.
We
have prepared this prospectus to allow the selling stockholders or their successors, assignees or other permitted transferees to sell
or otherwise dispose of, from time to time, up to 2,022,913 shares of our common stock, which are comprised of (i) 409,531 Common Shares,
(ii) 248,327 shares of common stock issuable upon the exercise of the Pre-Funded Warrants, (iii) 657,858 shares of common stock issuable
upon the exercise of the Amended Warrants, (iv) 657,858 shares of common stock issuable upon the exercise of the Warrants, and (v) 49,339
shares of common stock issuable upon the exercise of the Wainwright Warrants.
July
2022 Private Placement
On
July 1, 2022, we entered into the July 2022 Purchase Agreement with certain institutional and accredited investors for the issuance and
sale of 657,858 shares of common stock (or pre-funded warrants) and warrants to purchase up to an aggregate of 657,858 shares of common
stock at a combined purchase price of $6.10 per share of common stock (or pre-funded warrant) and associated warrant. The Pre-Funded
Warrants are exercisable at a price of $0.00001 per share, are exercisable immediately upon issuance and are exercisable until the Pre-Funded
Warrants are exercised in full. The Warrants are exercisable at an exercise price of $5.85 per share, are exercisable immediately upon
issuance and have a term of exercise equal to five and one-half years from the date of issuance. The July 2022 Private Placement closed
on July 7, 2022.
A
holder of the Pre-Funded Warrants, the Amended Warrants or the Warrants may not exercise its Pre-Funded Warrants, Amended Warrants or
Warrants, respectively, to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the
election of the holder prior to the date of issuance, 9.99%) of our outstanding shares of common stock immediately after exercise, except
that upon at least 61 days’ prior notice from the holder to us, the holder may increase the beneficial ownership limitation to
up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
In
connection with the July 2022 Private Placement, we entered into the Registration Rights Agreement with the purchasers under the July
2022 Purchase Agreement, pursuant to which, among other things, we agreed to prepare and file with the Securities and Exchange Commission,
by the 15th calendar day following the date of the Registration Rights Agreement, a registration statement on Form S-3, or
another such appropriate form, to register for resale the shares of common stock issued pursuant to the July 2022 Purchase Agreement
and issuable upon the exercise of the Pre-Funded Warrants and the Warrants, as applicable. We have agreed to use best efforts to have
the registration statement declared effective as promptly as practical thereafter, and in any event, no later than the 45th
calendar day following the date of the Registration Rights Agreement. In addition, we agreed that upon the registration statement being
declared effective under the Securities Act, we will use our best efforts to maintain the effectiveness of the registration statement
until the date that (i) the selling stockholders have sold all of the shares of common stock registrable under the Registration Rights
Agreement or (ii) such shares may be resold by the selling stockholders pursuant to Rule 144 of the Securities Act, without the requirement
for us to be in compliance with the current public information required under such rule and without volume or manner-of-sale restriction.
In
connection with the July 2022 Private Placement, we entered into the Warrant Amendment Agreements with each of the investors in which
we agreed to amend certain existing warrants pursuant to purchase up to an aggregate of 657,858 shares of our common stock that were
previously issued to the investors, with exercise prices ranging from $18.50 to $38.00 per share and expiration dates ranging from July
22, 2026 to November 1, 2026, effective upon the closing of the July 2022 Private Placement. The Amended Warrants have a reduced exercise
price of $5.85 per share and expire five and one-half years following the closing of the July 2022 Private Placement.
Wainwright
served as our exclusive placement agent in connection with the July 2022 Private Placement. Pursuant to the Engagement Letter, we paid
Wainwright (i) a total cash fee equal to 7.5% of the aggregate gross proceeds of the July 2022 Private Placement, (ii) a management fee
equal to 1.0% of the gross proceeds of the July 2022 Private Placement; and (iii) a non-accountable expense allowance of $85,000. In
addition, we issued to Wainwright or its designees the Wainwright Warrants to purchase up to 49,339 shares of our common stock at an
exercise price equal to $7.625. The Wainwright Warrants were exercisable immediately upon issuance and have a term of five and one-half
years from the date of issuance.
We
are registering the Common Shares, and the shares of common stock issuable upon the exercise of the Pre-Funded Warrants, the Amended
Warrants, the Warrants and the Wainwright Warrants in order to permit the selling stockholders to offer such shares for resale from time
to time pursuant to this prospectus. The selling stockholders may also sell, transfer or otherwise dispose of all or a portion of their
shares in transactions exempt from the registration requirements of the Securities Act, or pursuant to another effective registration
statement covering those shares.
Relationships
with the selling stockholders
Except
as described below, none of the selling stockholders has, or within the past three years has had, any position, office or other material
relationship with us.
Each
of Michael Vasinkevich, Noam Rubinstein, Craig Schwabe and Charles Worthman are associated persons of Wainwright, which served as our
underwriter for the public offering we consummated in December 2020, our placement agent in connection with the registered direct offering
we consummated in December 2020, our placement agent in connection with the public offering we consummated in February 2021, our placement
agent in connection with the private placement we consummated in April 2021 (the “April 2021 Private Placement”), our placement
agent in connection with the registered direct offering and concurrent private placement we consummated in July 2021 (together, the “July
2021 Offerings”), our placement agent in connection with the first registered direct offering and concurrent private placement
we consummated in August 2021 (together, the “First August 2021 Offerings”), our placement agent in connection with the second
registered direct offering and concurrent private placement we consummated in August 2021 (together, the “Second August 2021 Offerings”),
our placement agent in connection with the private placement we consummated in November 2021 (the “November 2021 Private Placement”),
and our placement agent in connection with the July 2022 Private Placement, for each of which Wainwright received compensation.
Each
of Armistice Capital Master Fund Ltd., Cavalry Fund I LP and Lind Global Macro Fund, LP purchased securities in the April 2021 Private
Placement, the July 2021 Offerings, the First August 2021 Offerings, the Second August 2021 Offerings and the November 2021 Private Placement.
Lind Global Fund II LP purchased securities in the July 2021 Offerings, the First August 2021 Offering, the Second August 2021 Offerings
and the November 2021 Private Placement. Intracoastal Capital LLC purchased securities in the July 2021 Offerings, the First August 2021
Offerings and the Second August 2021 Offerings. Iroquois Capital Investment Group purchased securities in the July 2021 Offerings and
the First August 2021 Offerings. Iroquois Master Fund purchased securities in the July 2021 Offerings. Each of Bigger Capital Fund, LP
and District 2 Capital Fund LP purchased securities in the April 2021 Private Placement.
Information
About Selling Stockholders Offering
The
shares of common stock being offered by the selling stockholders are the Common Shares issued pursuant to the July 2022 Purchase Agreement,
and the shares of common stock issuable to the selling stockholders upon the exercise of the Pre-Funded Warrants, the Amended Warrants,
the Warrants and Wainwright Warrants. For additional information regarding the issuances of the Common Shares, the Pre-Funded Warrants,
the Amended Warrants, the Warrants and the Wainwright Warrants, see “—July 2022 Private Placement” above. We are registering
the Common Shares and the shares of common stock underlying the Pre-Funded Warrants, the Amended Warrants, the Warrants and the Wainwright
Warrants in order to permit the selling stockholders to offer the shares for resale from time to time.
The
table below lists the selling stockholders and other information regarding the ownership of the shares of common stock by each of the
selling stockholders. The second column lists the number of shares of common stock owned by each selling stockholder, based on its ownership
of the shares of common stock and securities convertible or exercisable into shares of common stock, as of July 14, 2022, assuming exercise
of the securities exercisable into shares of common stock held by the selling stockholders on that date, if applicable, without regard
to any limitations on conversions or exercises.
The
third column lists the shares of common stock being offered pursuant to this prospectus by the selling stockholders.
In
accordance with the terms of the Registration Rights Agreement and the Warrant Amendment Agreements, as applicable, this prospectus generally
covers the resale of the sum of (i) the maximum number of Common Shares, (ii) the maximum number of Pre-Funded Warrant Shares, (iii)
the maximum number of Amended Warrant Shares, (iv) the maximum number of Warrant Shares, and (v) the maximum number of Wainwright Warrant
Shares. The table below assumes that the outstanding Pre-Funded Warrants, Amended Warrants, Warrants and Wainwright Warrants were exercised
in full as of the trading day immediately preceding the date this registration statement was initially filed with the Securities and
Exchange Commission, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment
as provided in the July 2022 Purchase Agreement, without regard to any limitations on the exercise of the Pre-Funded Warrants, the Amended
Warrants, the Warrants and the Wainwright Warrants. The fourth column assumes the sale of all of the shares offered by the selling stockholders
pursuant to this prospectus.
Under
the terms of the Pre-Funded Warrants, the Amended Warrants, the Warrants and the Wainwright Warrants, a selling stockholder may not exercise
the Pre-Funded Warrants, the Amended Warrants, the Warrants or the Wainwright Warrants to the extent such exercise would cause such selling
stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would
exceed 4.99% (or 9.99% at the election of the holder prior to the date of issuance), of our then outstanding common stock following such
exercise, excluding for purposes of such determination shares of common stock issuable upon the exercise of such Pre-Funded Warrants,
Amended Warrants, Warrants or Wainwright Warrants which have not been exercised. The number of shares in the second and fourth columns
do not reflect this limitation. The selling stockholders may sell all, some or none of their shares in this offering. See “Plan
of Distribution.”
Name
of Selling Stockholder | |
Number
of shares of common stock owned prior to offering | |
Maximum
number of shares of common stock to be sold pursuant to this Prospectus | |
Number
of shares of common stock owned after offering | |
Percentage
of common stock owned after offering |
| |
| |
| |
| |
|
Armistice
Capital Master Fund Ltd. (1) | |
| 1,314,981 | | |
| 1,314,981 | (2) | |
| 0 | | |
| 0 | % |
Bigger
Capital Fund, LP(3) | |
| 25,002 | | |
| 25,002 | (4) | |
| 0 | | |
| 0 | % |
Cavalry
Fund I LP (5) | |
| 108,723 | | |
| 108,723 | (6) | |
| 0 | | |
| 0 | % |
District
2 Capital Fund LP(3) | |
| 25,002 | | |
| 25,002 | (7) | |
| 0 | | |
| 0 | % |
Intracoastal
Capital, LLC (8) | |
| 99,888 | | |
| 99,888 | (9) | |
| 0 | | |
| 0 | % |
Iroquois
Capital Investment Group LLC (10) | |
| 14,079 | | |
| 14,079 | (11) | |
| 0 | | |
| 0 | % |
Iroquois
Master Fund Ltd. (10) | |
| 32,862 | | |
| 32,862 | (12) | |
| 0 | | |
| 0 | % |
Lind
Global Macro Fund, LP (13) | |
| 197,352 | | |
| 197,352 | (14) | |
| 0 | | |
| 0 | % |
Lind
Global Fund II LP (13) | |
| 155,685 | | |
| 155,685 | (15) | |
| 0 | | |
| 0 | % |
Michael
Vasinkevich (16) | |
| 101,886 | | |
| 31,639 | (17) | |
| 70,247 | | |
| 2.79 | % |
Noam
Rubinstein (16) | |
| 34,955 | | |
| 10,855 | (18) | |
| 24,100 | | |
| * | |
Craig
Schwabe (16) | |
| 20,456 | | |
| 6,352 | (19) | |
| 14,104 | | |
| * | |
Charles
Worthman (16) | |
| 1,589 | | |
| 493 | (20) | |
| 1,096 | | |
| * | |
| |
| | | |
| | | |
| | | |
| | |
*
Less than 1% | |
| | | |
| | | |
| | | |
| | |
(1) |
The
shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the “Master Fund”),
and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (“Armistice Capital”), as the investment
manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd
disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. The selling
stockholder’s address is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022. The Master Fund may
not exercise the Warrants to the extent such exercise would cause the Master Fund, together with its affiliates and attribution parties,
to beneficially own a number of shares of common stock which would exceed 9.99% of our then outstanding common stock following such
exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such securities which have
not been so exercised. |
(2) |
Represents
(i) 190,000 Common Shares issued in the July 2022 Private Placement, (ii) 248,327 shares of common stock issuable upon the exercise
of the Pre-Funded Warrants, (iii) 438,327 shares of common stock issuable upon the exercise of the Amended Warrants, and (iv) 438,327
shares of common stock issuable upon the exercise of the Warrants. |
(3) |
Michael
Bigger, the managing member of the general partner of Bigger Capital Fund, LP, has sole voting and dispositive power over the securities
held by Bigger Capital Fund, LP. Mr. Bigger, the managing member of the general partner of District 2 Capital Fund LP, has sole voting
and dispositive power over the securities held by District 2 Capital Fund LP. The business address of District 2 Capital Fund LP
is 175 West Carver, Huntington, NY, 11743. The business address of Bigger Capital Fund, LP is 2250 Red Springs Drive, Las Vegas,
NV 89135 |
(4) |
Represents
(i) 8,334 Common Shares issued in the July 2022 Private Placement, (ii) 8,334 shares of common stock issuable upon the exercise of
the Amended Warrants, and (iii) 8,334 shares of common stock issuable upon the exercise of the Warrants. |
(5) |
Thomas
Walsh, manager of Cavalry Fund I LP, has sole voting and dispositive power over the securities held by Cavalry Fund I LP. Mr. Walsh,
manager of Cavalry Special Ops Fund LLC, has sole voting and dispositive power over the securities held by Cavalry Special Ops Fund
LLC. The selling stockholder’s address is 82 East Allendale Road, Suite 5B, Saddle River, New Jersey 07458. Cavalry Fund I
LP and Cavalry Special Ops Fund LLC may not exercise the Warrants to the extent such exercise would cause Cavalry Fund I LP or Cavalry
Special Ops Fund LLC, together with their affiliates and attribution parties, to beneficially own a number of shares of common stock
which would exceed 4.99% of our then outstanding common stock following such exercise, or, upon notice to us, 9.99% of our then outstanding
common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise
of such securities which have not been so exercised. |
(6) |
Represents
(i) 36,241 Common Shares issued in the July 2022 Private Placement, (ii) 36,241 shares of common stock issuable upon the exercise
of the Amended Warrants, and (iii) 36,241 shares of common stock issuable upon the exercise of the Warrants. |
(7) |
Represents
(i) 8,334 Common Shares issued in the July 2022 Private Placement, (ii) 8,334 shares of common stock issuable upon the exercise of
the Amended Warrants, and (iii) 8,334 shares of common stock issuable upon the exercise of the Warrants. |
(8) |
Mitchell
P. Kopin and Daniel B. Asher, each of whom are managers of Intracoastal Capital, LLC (“Intracoastal”), have shared voting
control and investment discretion over the securities reported herein that are held by Intracoastal. The selling stockholder’s
address is 245 Palm Trail, Delray Beach, FL 33483. Intracoastal may not exercise the Warrants to the extent such exercise would cause
Intracoastal, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which
would exceed 4.99% of our then outstanding common stock following such exercise, or, upon notice to us, 9.99% of our then outstanding
common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise
of such securities which have not been so exercised. |
(9) |
Represents
(i) 33,296 Common Shares issued in the July 2022 Private Placement, (ii) 33,296 shares of common stock issuable upon the exercise
of the Amended Warrants, and (iii) 33,296 shares of common stock issuable upon the exercise of the Warrants. |
(10) |
Richard
Abbe has the sole authority and responsibility for the investments made on behalf of Iroquois Capital Investment Group LLC (“ICIG”)
as its managing member and shares authority and responsibility for the investments made on behalf of Iroquois Master Fund Ltd. (the
“Iroquois Master Fund”) with Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe
may be deemed to be the beneficial owner of all shares of common stock held by and underlying the securities reported herein (subject
to the beneficial ownership blockers) held by Iroquois Master Fund and ICIG. The selling stockholder’s address is 125 Park
Ave., 25th Fl. NY, NY 10017. ICIG and Iroquois Master Fund may not exercise the Warrants to the extent such exercise would cause
ICIG or Iroquois Master Fund, together with their affiliates and attribution parties, to beneficially own a number of shares of common
stock which would exceed 4.99% of our then outstanding common stock following such exercise, or, upon notice to us, 9.99% of our
then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable
upon exercise of such securities which have not been so exercised. |
(11) |
Represents
(i) 4,693 Common Shares issued in the July 2022 Private Placement, (ii) 4,693 shares of common stock issuable upon the exercise of
the Amended Warrants, and (iii) 4,693 shares of common stock issuable upon the exercise of the Warrants. |
(12) |
Represents
(i) 10,954 Common Shares issued in the July 2022 Private Placement, (ii) 10,954 shares of common stock issuable upon the exercise
of the Amended Warrants, and (iii) 10,954 shares of common stock issuable upon the exercise of the Warrants. |
(13) |
Jeff
Easton is the Managing Member of Lind Global Partners, LLC, which is the General Partner and the Investment Manager of Lind Global
Macro Fund LP and Lind Global Fund II LP, respectively, and in such capacity has the right to vote and dispose of the securities
held by such entities. Mr. Easton disclaims beneficial ownership over the securities listed except to the extent of his pecuniary
interest therein. The address for Lind Global Macro Fund LP and Lind Global Fund II LP is 444 Madison Avenue, 41st Floor, New York,
NY 10022. Lind Global Partners, LLC and Lind Global Fund II LP may not exercise the Warrants to the extent such exercise would cause
Lind Global Partners, LLC or Lind Global Fund II LP, together with their affiliates and attribution parties, to beneficially own
a number of shares of common stock which would exceed 4.99% of our then outstanding common stock following such exercise, or, upon
notice to us, 9.99% of our then outstanding common stock following such exercise, excluding for purposes of such determination shares
of common stock issuable upon exercise of such securities which have not been so exercised. |
(14) |
Represents
(i) 65,784 Common Shares issued in the July 2022 Private Placement, (ii) 65,784 shares of common stock issuable upon the exercise
of the Amended Warrants, and (iii) 65,784 shares of common stock issuable upon the exercise of the Warrants. |
(15) |
Represents
(i) 51,895 Common Shares issued in the July 2022 Private Placement, (ii) 51,895 shares of common stock issuable upon the exercise
of the Amended Warrants, and (iii) 51,895 shares of common stock issuable upon the exercise of the Warrants. |
(16) |
The
selling stockholder was issued compensation warrants as a designee of Wainwright in connection with the June 2022 Private Placement.
Each selling stockholder has sole voting and dispositive power over the securities held. The business address is c/o H.C. Wainwright
& Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022. Each selling stockholder may not exercise the Wainwright Warrants
to the extent such exercise would cause each selling stockholder, together with his affiliates and attribution parties, to beneficially
own a number of shares of common stock which would exceed 4.99% of our then outstanding common stock following such exercise, or,
upon notice to us, 9.99% of our then outstanding common stock following such exercise, excluding for purposes of such determination
shares of common stock issuable upon exercise of such securities which have not been so exercised. |
(17) |
Represents
31,639 shares of common stock issuable upon the exercise of the Wainwright Warrants. |
(18) |
Represents
10,855 shares of common stock issuable upon the exercise of the Wainwright Warrants. |
(19) |
Represents
6,352 shares of common stock issuable upon the exercise of the Wainwright Warrants. |
(20) |
Represents
493 shares of common stock issuable upon the exercise of the Wainwright Warrants. |
DESCRIPTION
OF SECURITIES TO BE REGISTERED
Authorized
Capital Stock
We
have authorized 220,000,000 shares of capital stock, of which 200,000,000 are shares of common stock and 20,000,000 are shares of “blank
check” preferred stock. On July 14, 2022, there were 2,419,688 shares of common stock issued and outstanding. We currently
have 1,663,008 shares of preferred stock designated as Series A Preferred Stock, 200,000 shares of preferred stock designated as Series
B Preferred Stock, 2,000,000 shares of preferred stock designated as Series C Preferred Stock, 13,000 shares of preferred stock designated
as Series E Convertible Preferred Stock, 6,500 shares of preferred stock designated as Series E-1 Convertible Preferred Stock,
4,698 shares of preferred stock designated as Series F Convertible Preferred Stock, 13,000 shares of preferred stock designated as Series
G Preferred Convertible Stock, 6,500 shares of preferred stock designated as Series G-1 Convertible Preferred Stock, 9,000,000 shares
of preferred stock designated as Series H Convertible Preferred Stock, and 40,000 shares of preferred stock designated as Series J Preferred
Stock. The authorized and unissued shares of common stock and the authorized and undesignated shares of preferred stock are available
for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange
on which our securities may be listed. Unless approval of our stockholders is so required, our Board does not intend to seek stockholder
approval for the issuance and sale of our common stock or preferred stock.
As
of July 14, 2022, we had 511 holders of record of our shares of common stock.
PLAN
OF DISTRIBUTION
Each
selling stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time,
sell any or all of their securities covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the securities
are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any one or more
of the following methods when selling securities:
|
● |
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
|
|
|
|
● |
block
trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
as principal to facilitate the transaction; |
|
|
|
|
● |
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account; |
|
|
|
|
● |
an
exchange distribution in accordance with the rules of the applicable exchange; |
|
|
|
|
● |
privately
negotiated transactions; |
|
|
|
|
● |
settlement
of short sales; |
|
|
|
|
● |
in
transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated
price per security; |
|
|
|
|
● |
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
|
|
|
|
● |
a
combination of any such methods of sale; or |
|
|
|
|
● |
any
other method permitted pursuant to applicable law. |
The
selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.
Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.
In
connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The
selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.
We
are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify
the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
us to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect
or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar
effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state
securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the selling stockholders or any other person. We will make copies of this prospectus available to the selling stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).
LEGAL
MATTERS
The
validity of the securities offered by this prospectus will be passed upon by Haynes and Boone, LLP, New York, New York.
EXPERTS
The
financial statements as of January 1, 2022 and January 2, 2021 and for each of the two years in the period ended January 1, 2022 incorporated
by reference in this prospectus have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public
accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report
on the financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
WHERE
YOU CAN FIND MORE INFORMATION
We
are subject to the informational requirements of the Exchange Act and in accordance therewith file annual, quarterly and current reports,
proxy statements and other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains
a website that contains reports, proxy and information statements and other information regarding registrants that file electronically
with the Securities and Exchange Commission. The address of the Securities and Exchange Commission’s website is www.sec.gov.
We
make available free of charge on or through our website at www.staffing360solutions.com, our Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Exchange Act as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Securities
and Exchange Commission.
We
have filed with the Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended, relating
to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information
about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can
obtain a copy of the registration statement for free at www.sec.gov. The registration statement and the documents referred to below under
“Incorporation of Certain Information By Reference” are also available on our website, www.staffing360solutions.com.
We
have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of
this prospectus.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
Securities and Exchange Commission allows us to “incorporate by reference” the information we have filed with it, which means
that we can disclose important information to you by referring you to those documents. The information we incorporate by reference is
an important part of this prospectus, and later information that we file with the Securities and Exchange Commission will automatically
update and supersede this information. We incorporate by reference the documents listed below and any future documents (excluding information
furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the Securities and Exchange Commission pursuant to Sections l3(a),
l3(c), 14 or l5(d) of the Exchange subsequent to the date of this prospectus and prior to the termination of the offering:
|
● |
Our
Annual Report on Form 10-K for the year ended January 1, 2022, filed with the Securities and Exchange Commission on June 24,
2022; |
|
|
|
|
● |
Our
Quarterly Report on Form 10-Q for the quarter ended April 2, 2022, filed with the Securities
and Exchange Commission on July 14, 2022;
|
|
● |
The
description of our common stock contained in our Registration Statement on Form 8-A filed with the Securities and Exchange Commission
on September 28, 2015, as amended and supplemented by the description of our common stock contained in Exhibit 4.7 to our Annual
Report on Form 10-K for the year ended January 1, 2022, filed with the Securities and Exchange Commission on June 24, 2022, including
any amendment or reports filed for the purpose of updating such description; and |
|
|
|
|
● |
Our
Current Reports on Form 8-K, filed with the Securities and Exchange Commission on January 28, 2022, March 1, 2022, April 14, 2022,
April 20, 2022, April 22, 2022, May 4, 2022, May 19, 2022 (as amended on Form 8-K/A on May 20, 2022), May 24, 2022, May 26, 2022,
June 23, 2022 and July 7, 2022. |
All
filings filed by us pursuant to the Exchange Act after the date of the initial filing of this registration statement and prior to the
effectiveness of such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall also
be deemed to be incorporated by reference into the prospectus.
You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide
you with different information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to
be modified or superseded for the purposes of this prospectus to the extent that a later statement contained in this prospectus or in
any other document incorporated by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified
or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should not assume
that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents
incorporated by reference in this prospectus.
We
will provide without charge to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any
or all of the reports or documents that have been incorporated by reference in this prospectus but not delivered with this prospectus
(other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus). Any
such request should be addressed to us at:
Staffing
360 Solutions, Inc.
Attn:
Chief Financial Officer
757
Third Ave., 27th Floor
New
York, New York 10017
(646)
507-5710
You
may also access the documents incorporated by reference in this prospectus through our website at www.staffing360solutions.com. Except
for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated
in this prospectus or the registration statement of which it forms a part.
2,022,913
Shares
COMMON
STOCK
PROSPECTUS
July 20, 2022
Staffing 360 Solutions (NASDAQ:STAF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Staffing 360 Solutions (NASDAQ:STAF)
Historical Stock Chart
From Mar 2023 to Mar 2024